Archives: Agenda

• Centralizing GenAI governance through LLM Gateways for policy compliance
• Simplified integration with a unified API for various LLM providers
• Implementing guardrails to filter PII and toxic content for responsible AI use
• Monitoring techniques for real-time AI usage tracking and cost optimization
• Balancing innovation and control as demonstrated by case studies in financial institutions

Learning from industry successes in reducing emissions, improving circularity, and maintaining affordability

Interviewee: Fatih Savci, Fleet management of rail vehicle technology and maintenance, WESTbahn

Interviewer: Patrick Atack, Editor of Railway Technology, GlobalData

• Cell therapies market landscape – current and future
• Key industry trends
• Industry forecast

• An overview of the FDA’s latest guidelines and requirements for DCTs, highlighting key aspects such as the integration of digital health technologies, remote monitoring, and the adherence to Good Clinical Practice (GCP) principles, as well as ensuring innovative trials maintain the highest standards of safety, efficacy, and data integrity.
• Discussion of the FDA’s collaborative efforts with other regulatory bodies, promoting harmonized standards and facilitating global acceptance of DCT methodologies.
• Adhering to the FDA’s comprehensive regulatory requirements so sponsors can navigate the complexities of DCTs and contribute to the evolution of clinical trials and the accelerated development of innovative medical treatments